Ascendis Pharma A/S
HealthcareNASDAQ:ASND · NASDAQ Global Select
+$5.65 today
Vol 0.40M · Avg 0.64M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
134.6%
avg 26.6%
ROIC
-18.2%
avg -47.1%
ROA
-16.8%
avg -39.2%
Analysis
ROE is currently the strongest return metric at 134.6% versus its period average of 26.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph Kelly | Head of U.S. Commercial of Endocrinology | — | — | 57 | — | — |
Mads Bodenhoff | Senior Vice President, Head of Finance & Principal Accounting Officer | — | — | 56 | $0.00 | <0.01% |
Kennett Sprogoe | Executive Vice President and Head of Research & Product Development | — | — | 47 | $19,460.00 | 0.03% |
Chad Fugure | Vice President of Investor Relations | — | — | — | — | — |
Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | — | — | 65 | $0.00 | <0.01% |
Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director | — | — | 66 | $384,933.00 | 0.62% |
Scott T. Smith | Chief Financial Officer, Executive Vice President & Member of Executive Board | — | — | 52 | $4,367.00 | <0.01% |
Stina Singel | Executive Vice President & Head of Clinical Development for Oncology | — | — | 52 | — | — |
Michael Wolff Jensen | Executive Vice President, Chief Legal Officer & Member of the Executive Board | — | — | 55 | $0.00 | <0.01% |
Pedersen Anni Lotte Kirstine Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board | — | — | 65 | $19,460.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$284,412.50
Sells
1
$4.64M
Net Sentiment
$4.36M
Net selling
Most Active
BIENAIME JEAN JACQUES
5 transactions
Analysis
Insiders reported 7 buys worth $284,412.50 and 1 sells worth $4.64M over the last 12 months. That adds up to net selling of $4.36M. BIENAIME JEAN JACQUES was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | -39.1% | +60.1% (14yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -39.1% over three years. Forward estimates point to Revenue at +60.1% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.70B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.79B
Moderna, Inc.
NASDAQ:MRNA
$19.99B
Guardant Health, Inc.
NASDAQ:GH
$17.25B
Exelixis, Inc.
NASDAQ:EXEL
$13.36B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.14B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.12B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.07B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.83B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.77B
Who manages ASND?
Ascendis Pharma A/S (ASND) lists 10 active executives. The top listed executive is Joseph Kelly, Head of U.S. Commercial of Endocrinology.
Are ASND insiders buying or selling?
Recent insider activity shows net selling of $4.36M.
Explore More
Continue the stock analysis
Jump to another research area for this company.